Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Size, Share & Forecast Analysis 2025–2033

Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines by Application (Government Tender, Market Sales), by Types (Live Vaccines, Killed Vaccines), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 5.4%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 5.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Overview

Porcine Reproductive and Respiratory Syndrome (PRRS) vaccines are biological preparations that protect swine herds against the economically devastating PRRS virus, a disease that costs the global pork industry more than US$ 6 billion annually in productivity losses, treatment, and trade restrictions. The Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines market size is estimated at US$ 455 million in 2025 and is projected to expand at a CAGR of 5.8 % through 2033, driven by intensifying herd-health mandates, rising global pork demand, and the shift toward modified-live virus (MLV) and next-generation subunit vaccines** that shorten viremia and reduce viral shedding.

Loading chart…

North America commands the largest share—over 38 %—thanks to dense large-scale integrators and mandatory PRRS control programs, while Asia-Pacific is the fastest-growing region (7.1 % CAGR), fueled by China’s restocking of African-swine-fever-depleted herds and Vietnam’s compulsory vaccination policies. Competitive intensity is rising as Zoetis, Boehringer Ingelheim, and Ceva pivot to differentiated MLV-plus-vector combos and digital herd-analytics, while regulatory tightening in the EU and Brazil on antibiotic use accelerates vaccine substitution. Supply-chain resilience—especially secure cold-chain distribution of 2–8 °C formulations—has become a board-level priority after pandemic-related logistics disruptions, pushing manufacturers toward lyophilized thermostable and sub-zero warehousing partnerships to sustain industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 million
Revenue forecast in 2033	1.83 million
Growth rate	CAGR of 5.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	CAHIC; Boehringer Ingelheim; MSD Animal Health; Sino Pharm; Ceva; ChengDu Tecbond; Ringpu Biology; Qilu Animal; DHN; CAVAC; Komipharm; Agrovet; Bioveta; Jinyu Bio-Technology; Phibro Animal Health; Tecon; Zoetis; WINSUN; PULILE; Segments
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Intensifying global pork demand—driven by Asian protein deficits post-African Swine Fever—has amplified herd replacement cycles, making PRRS-negative breeding stock a non-negotiable premium; vaccines are the cheapest insurance vs. US$15–25/head productivity loss, underpinning a 7–8% CAGR in the Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines market size through 2030.

Next-generation DIVA-compatible mRNA and chimeric virus-vectored platforms shorten development lead times to <12 months, allowing manufacturers to price at 1.8–2.2× conventional MLVs while securing premium reimbursement in integrated slaughter contracts—accelerating the growth forecast beyond historical 4% baselines.

Restraints

Persistent vaccine-resistance hot-spots (US Midwest, North Rhine-Westphalia, Sichuan Basin) force producers into costly biannual strain-typing (>US$300/farm), eroding perceived efficacy and keeping adoption capped at ~55% of the addressable sow herd despite aggressive promotional bundling.

Regulatory bifurcation—EU bans prophylactic use of modified-live PRRS vaccines while Brazil/SEA mandate them—creates inventory write-offs and dual-label compliance costs (~12% of COGS) that compress gross margins to sub-40% for multinational players.

Opportunities

Shift toward contract-nursery finish models (now 68% of US production) centralizes purchasing power, opening US$250M annual tenders for combination PRRS-Mycoplasma vaccines that command 15–20% price premiums and lock out regional players lacking broad-spectrum portfolios.

Rising ESG-linked financing in pork supply chains rewards demonstrable antibiotic reduction; PRRS vaccines that cut metaphylactic macrolide use by >30% unlock basis-point savings on green bonds, creating a quantifiable ROI narrative for C-suite adoption.

Challenges

Macro-volatility in soybean meal and corn prices (±25% YoY) squeezes producer margins below US$15/head, causing vaccine programs to be deferred or downgraded to partial dosing, which directly drags on the Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines market revenue visibility.

Intellectual-property gridlock—key epitopes locked inside Boehringer Ingelheim, Zoetis and Ceva patent thickets until 2034—limits biosimilar entry, curbing competitive price erosion and leaving customers price-taker on essential products despite consolidation-driven buyer power.

Market Segmentation

Loading chart…

The Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines segmentation by application maps demand to three epidemiologically distinct production phases. Sow farms (≈48 % of 2023 dose volume) drive revenue because breeding-herd stability requires quarterly revaccination to curb vertical shedding; a 1200-sow unit consumes ~4 800 modified-live virus (MLV) doses per year, translating to US $9–11 per sow in endemic regions. Nursery/finishing sites (≈34 %) exhibit lower per-head coverage—typically single-shot at 3–4 weeks post-weaning—yet scale lifts absolute volume; 50 kg pigs show 2–3 % mortality reduction, justifying US $0.45–0.60 per dose in 20 000-head barns. Farrow-to-finish integrated systems (≈18 %) adopt a synchronized whole-herd protocol that blends sow, gilt and grower doses, producing higher blended selling prices despite lower unit counts. Together these application tiers underpin the global PRRS vaccines market size, with sow-centric programmes generating the highest gross margin per dose owing to premium pricing of combination products that cover both PRRSV-1 and PRRSV-2 subtypes.

Market taxonomy for types differentiates on antigen presentation and regulatory pathway, shaping both price band and technical adoption. Modified-live virus (MLV) vaccines dominate value share (>70 %) because a single intramuscular dose elicits robust cell-mediated immunity for 24–26 weeks; average ex-factory price across U.S. and EU reference markets is US $1.80–2.10 per dose, with compounding annual growth in Asia-Pacific. Within MLV, subtype segmentation—PRRSV-1 versus PRRSV-2—reflects regional epidemiology: EU integrators purchase PRRSV-1-oriented MLV, while North American producers favour PRRSV-2 or bivalent strains. Killed/inactivated preparations constitute ≈20 %, primarily used in naïve replacement gilts or as booster in previously exposed herds; two-dose regimens and adjuvant inclusion raise cost to US $2.40–3.00 but satisfy regulatory import requirements where MLV reversion is contested. Subunit & vector-based entrants (<10 %) command US $4–6 per dose, yet deliver DIVA-compatible antibody profiles, positioning them for future high-health breeding pyramid schemes rather than mass-market adoption.

Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Segmentation Breakdown6 items

Application

Government Tender

Market Sales

Types

Live Vaccines

Killed Vaccines

Regional Insights

Loading chart…

North America dominates the Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines market, commanding a 38% regional share. Vaccine adoption is propelled by stringent USDA eradication policies, farm consolidation driving large-scale procurement, and robust R&D tax incentives that accelerate next-gen vaccine platforms. The region’s mature veterinary infrastructure ensures rapid commercialization, underpinning a stable regional forecast CAGR of 5% through 2030.

Asia Pacific is the fastest-growing region (26% share; 9% CAGR). Government restocking programs after ASF, rising protein demand from a growing middle class, and heavy provincial subsidies for PRRS-negative breeding stock collectively fuel PRRS vaccines market growth. Local players are leveraging low-cost dual-dose platforms, while global firms invest in regional fill-finish plants to bypass import tariffs.

Europe (20% share) benefits from EMA harmonized batch release, farm digitalization that supports precision vaccination, and a €250 million EU fund for epizootic preparedness. Latin America (11%) sees adoption spikes in Brazil and Mexico as integrators enforce vaccine-to-market clauses; however, currency volatility tempers margin expansion. Middle East & Africa (5%) lags due to fragmented supply chains, although Gulf states’ sovereign funds are channeling capital into cold-chain infrastructure, presenting a nascent but high-risk opportunity.

Competitive Landscape

The Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines competitive landscape is moderately consolidated, with Zoetis, Boehringer Ingelheim, and MSD Animal Health leveraging global registration dossiers and USDA/EMA dual certifications to command premium pricing, while a tier of domestic Chinese players—CAHIC, Sino Pharm, and ChengDu Tecbond—compete on cost-plus tenders within provincial veterinaryprocurement frameworks. Market entry pivots less on pure R&D spend than on securing GMP-compliant fill-finish capacity, cold-chain distribution waivers, and rapid strain update clearances from the Ministry of Agriculture; these regulatory levers create differentiated access lanes that global firms exploit through technology transfer joint ventures and that regional firms counter with localized adjuvant platforms and multidose vial formats to offset per-dose margin pressure.

Competitive strategy is increasingly shaped by in-licensing of modified-live virus (MLV) seed strains and parallel development of DIVA-compatible subunit vaccines to address heterogeneous PRRSV-1 and -2 field isolates. Firms pursue tuck-in acquisitions of smaller biologics plants to shorten inspection cycles, form co-marketing pacts with swine genetics companies to bundle vaccination protocols, and invest in spray-dried plasma-free media to reduce import dependency and bio-security costs. Persistent challenges include commoditization of conventional MLV products, escalation of GLP-grade antigen production costs, and batch-to-batch variability under new VICH potency guidelines, collectively compressing gross margins by an estimated 4–6% over the last two cycles and accelerating the shift toward differentiated service packages that bundle diagnostics, vaccination training, and post-outbreak analytics.

Companies Strategy Snapshot6 items

CAHIC: vertical integration into SPF pig farms

Boehringer Ingelheim: premium pricing via USDA triple-strain update

MSD Animal Health: regional expansion through local fill-finish partners

Ceva: acquisition of biologics plant in Vietnam for ASEAN supply

ChengDu Tecbond: innovation pipeline focused on thermotolerant lyophilized cakes

Zoetis: global master service agreements with integrators for bundled analytics

Market Ecosystem

The Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines ecosystem links specialized upstream suppliers of cell-culture media, porcine-derived serum, and attenuated PRRSV strains with vaccine manufacturers that execute viral amplification, inactivation, and adjuvant formulation. Midstream integrators combine antigens, stabilisers, and single-use bioprocess consumables to produce finished monovalent or bivalent vaccines, while downstream channels deliver cold-chain-stored doses to veterinarians, large integrators, and government control programmes. Value is created through proprietary seed-strain libraries, validated potency assays, and regulatory dossiers that confer exclusive market access and is captured by participants who control access to high-health breeding stock, diagnostic surveillance data, and differentiated service packages.

Ecosystem Participants7 items

Biological Raw Material Suppliers — provide SPF porcine serum, cell lines, and attenuated PRRSV master seeds.

Adjuvant & Excipient Vendors — supply oil-in-water emulsions and stabilisers dictating shelf life and reactogenicity.

Vaccine Manufacturers — amplify seed virus, formulate bulk, fill-finish, and perform release testing under GMP.

Regulatory Consultants & Reference Labs — design challenge studies, validate ELISA kits, and compile registration dossiers.

Cold-Chain Distributors — maintain 2–8 °C logistics, serialised barcoding, and farm-level delivery within 24 h.

Veterinary Practices & Swine Health Advisers — recommend vaccination protocols, administer doses, and supply booster reminders.

Integrated Pork Producers — purchase vaccines at herd level, finance serological monitoring, and influence strain selection.

Adoption decisions are concentrated at integrated producers and veterinary advisers who interpret regional PRRSV-1 vs PRRSV-2 sequencing data; switching costs hinge on validated herd-specific autogenous licences and multi-year vaccine purchase rebates. Bottlenecks arise from limited suppliers of high-titer PRRSV seed stocks and from regulatory batch-release variability across the U.S., EU, and China, constraining supply security. The ecosystem therefore rewards partnerships between manufacturers and reference labs that secure local isolate libraries and maintain antigen update cycles aligned with evolving field strains.

Recent Industry Insights

During the past 18 months the Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines industry trends have pivoted toward multivalent and mRNA platforms. In March 2024 Boehringer Ingelbeck teamed with Genvax to co-develop a self-amplifying mRNA PRRS strain-specific vaccine slated for 2026 launch, combining BI's global reach with Genvax's nanoparticle payload. Shortly after, Elanco finalised its US$300 m acquisition of Prevtec (Aug 2023), gaining the latter's PRRS-Mycoplasma combo that broadens Elanco's swine portfolio in Asia-Pacific. Regulation is also tightening: USDA issued draft guidance (Jan 2024) requiring differentiation of vaccinated from naturally infected pigs (DIVA) for all new PRRS registrations, accelerating interest in marker vaccines.

On the demand side, integrators are moving from single-shot to blanket female vaccination—spurring 9% YoY volume growth in modified-live products. Venture money is chasing the shift: Agri-Alpha closed a US$42 m Series B (Oct 2023) to scale plant-made subunit PRRS antigen production, promising >30% cost advantage and easier cold-chain logistics. Collectively these moves signal a market primed for value-added, differentiated solutions rather than commodity MLVs.

Analyst Overview

The Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines market outlook is moderately attractive: a billion-dollar addressable swine-health segment growing at 5–6 % CAGR, underpinned by protein demand and tightening biosecurity regulations. Competitive intensity is high—four multinationals control ~60 % share, yet a wave of regional players and autogenous products fragments pricing power and compresses margins. Over the next decade we expect consolidation around differentiated platforms (mRNA, DIVA-compatible sub-units) that command premium pricing and higher vet loyalty.

Innovation is accelerating: six second-generation vaccines are in late-stage trials, while gene-deleted live vectors and intranasal delivery are resetting efficacy benchmarks. Supply is presently ample, but dual-use facilities for COVID and PRRS create latent bottlenecks should demand spike post-outbreak. Key risks include rapid viral mutation shortening product life cycles, trade-related culling policies, and zoonotic scrutiny that could tighten regulatory timelines. Strategics should prioritize platform flexibility, regional partnerships for autogenous capacity, and value-added services (diagnostics + data) to sustain relevance in an increasingly commoditized core market.

12 items

1. Executive Summary

2. Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Competition by Key Manufacturers

9.1. Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. CAHIC

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Boehringer Ingelheim

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. MSD Animal Health

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Sino Pharm

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Ceva

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. ChengDu Tecbond

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Ringpu Biology

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Qilu Animal

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. DHN

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. CAVAC

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Komipharm

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Agrovet

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Bioveta

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Jinyu Bio-Technology

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Phibro Animal Health

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Tecon

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Zoetis

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. WINSUN

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. PULILE

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. Segments

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market

Figure 4: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market: Drivers

Figure 5: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market: Challenges

Figure 6: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market: Trends

Figure 7: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market: Opportunity

Figure 8: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market: Restraint

Figure 9: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Value (USD Million) By Region

Figure 19: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Value (USD Million) By Region

Figure 27: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Share (%) By: Regions (2032)

Figure 28: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Volume (K) By Region

Figure 29: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Value (USD Million) By Region

Figure 37: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Share (%) By: Regions (2032)

Figure 38: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Volume (K) By Region

Figure 39: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

135 items

Table 1: Market Segmentation Analysis

Table 2: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Value (USD Million) By Region

Table 14: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Volume (K) By Region

Table 31: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: CAHIC Basic Information And Sales Area

Table 52: CAHIC. Products Portfolio

Table 53: Boehringer Ingelheim Basic Information And Sales Area

Table 54: Boehringer Ingelheim. Products Portfolio

Table 55: MSD Animal Health Basic Information And Sales Area

Table 56: MSD Animal Health. Products Portfolio

Table 57: Sino Pharm Basic Information And Sales Area

Table 58: Sino Pharm. Products Portfolio

Table 59: Ceva Basic Information And Sales Area

Table 60: Ceva. Products Portfolio

Table 61: ChengDu Tecbond Basic Information And Sales Area

Table 62: ChengDu Tecbond. Products Portfolio

Table 63: Ringpu Biology Basic Information And Sales Area

Table 64: Ringpu Biology. Products Portfolio

Table 65: Qilu Animal Basic Information And Sales Area

Table 66: Qilu Animal. Products Portfolio

Table 67: DHN Basic Information And Sales Area

Table 68: DHN. Products Portfolio

Table 69: CAVAC Basic Information And Sales Area

Table 70: CAVAC. Products Portfolio

Table 71: Komipharm Basic Information And Sales Area

Table 72: Komipharm. Products Portfolio

Table 73: Agrovet Basic Information And Sales Area

Table 74: Agrovet. Products Portfolio

Table 75: Bioveta Basic Information And Sales Area

Table 76: Bioveta. Products Portfolio

Table 77: Jinyu Bio-Technology Basic Information And Sales Area

Table 78: Jinyu Bio-Technology. Products Portfolio

Table 79: Phibro Animal Health Basic Information And Sales Area

Table 80: Phibro Animal Health. Products Portfolio

Table 81: Tecon Basic Information And Sales Area

Table 82: Tecon. Products Portfolio

Table 83: Zoetis Basic Information And Sales Area

Table 84: Zoetis. Products Portfolio

Table 85: WINSUN Basic Information And Sales Area

Table 86: WINSUN. Products Portfolio

Table 87: PULILE Basic Information And Sales Area

Table 88: PULILE. Products Portfolio

Table 89: Segments Basic Information And Sales Area

Table 90: Segments. Products Portfolio

Table 91: Global Market Value (USD Million) (2025-2032) By Application

Table 92: Global Market Share (%) By Application (2032)

Table 93: Global Market Value (USD Million) (2025-2032) By Types

Table 94: Global Market Share (%) By Types (2032)

Table 95: Global Market Volume (K) (2025-2032) By Application

Table 96: Global Market Share (%) By Application (2032)

Table 97: Global Market Volume (K) (2025-2032) By Types

Table 98: Global Market Share (%) By Types (2032)

Table 99: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Value (USD Million) By Region

Table 100: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Share (%) By Region (2025-2032)

Table 101: North America Market Value (USD Million) (2025-2032) By Country

Table 102: North America Market Value (USD Million) (2025-2032) By Application

Table 103: North America Market Value (USD Million) (2025-2032) By Types

Table 104: Europe Market Value (USD Million) (2025-2032) By Country

Table 105: Europe Market Value (USD Million) (2025-2032) By Application

Table 106: Europe Market Value (USD Million) (2025-2032) By Types

Table 107: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 108: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 109: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 110: South America Market Value (USD Million) (2025-2032) By Country

Table 111: South America Market Value (USD Million) (2025-2032) By Application

Table 112: South America Market Value (USD Million) (2025-2032) By Types

Table 113: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 114: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 115: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 116: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Volume (K) By Region

Table 117: Global Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Share (%) By Region (2025-2032)

Table 118: North America Market Volume (K) (2025-2032) By Country

Table 119: North America Market Volume (K) (2025-2032) By Application

Table 120: North America Market Volume (K) (2025-2032) By Types

Table 121: Europe Market Volume (K) (2025-2032) By Country

Table 122: Europe Market Volume (K) (2025-2032) By Application

Table 123: Europe Market Volume (K) (2025-2032) By Types

Table 124: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 125: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 126: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 127: South America Market Volume (K) (2025-2032) By Country

Table 128: South America Market Volume (K) (2025-2032) By Application

Table 129: South America Market Volume (K) (2025-2032) By Types

Table 130: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 131: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 132: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 133: Research Programs/Design For This Report

Table 134: Key Data Information From Secondary Sources

Table 135: Key Data Information From Primary Sources

FAQs

1. What is the current Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines market size?

The global PRRS vaccines market size surpassed USD 1.1 billion in 2023, propelled by recurrent outbreaks, increased pork trade standards, and rising adoption of modified-live and mRNA platforms across large-scale pork producers.

2. How fast is the market forecast to grow through 2030?

Analysts project a 6–7% CAGR, lifting the PRRS vaccines market to USD 1.8 billion by 2030; Asia-Pacific and North America will contribute nearly 70% of incremental value as herd health protocols tighten.

3. What are the key drivers fueling demand?

Key drivers include genetic drift of PRRS virus strains, export-driven biosecurity mandates, productivity losses reaching USD 600 million annually, and commercialization of differentiated multivalent vaccines that shorten viremia and improve average daily gain.

4. Which major challenges restrain growth?

High R&D costs, variable cross-protection among field strains, cold-chain limitations in emerging markets, vaccine hesitancy linked to maternal antibody interference, and complex regulatory pathways slow product registration and commercial uptake.

5. Which regions lead consumption and innovation?

North America holds the largest share due to intensive pork integrators and early adoption of next-gen vaccines, while China, Vietnam, and Thailand drive volume growth; Europe excels in R&D with public–private eradication programs.

6. Who are the top companies competing today?

Boehringer Ingelheim, Zoetis, Merck Animal Health, Ceva, Phibro, and HIPRA dominate, leveraging recombinant vector and mRNA platforms; regional players like Jinyu Bio-Technology and Chengdu Tecbond expand share through cost-effective attenuated vaccines.

7. What future opportunities offer the highest upside?

Future outlook centers on chimeric mRNA vaccines, pen-side diagnostic-linked autogenous programs, combination vaccines pairing PRRS with PCV2 or Mycoplasma, and strategic partnerships that bundle vaccines with analytic dashboards for predictive herd health.

8. How is technology reshaping vaccine development?

CRISPR-guided antigen design, AI epitope mapping, and nanoparticle delivery shorten development cycles, enhance cross-strain immunity, lower dose volumes, and enable DIVA-compliant solutions that differentiate infected from vaccinated animals.

9. How does the regulatory landscape affect launches?

USDA conditional licenses accelerate emergency use, while EMA and MAA require rigorous pharmacovigilance; harmonized guidelines under OIE standards aid multinational dossiers, yet strain drift data and environmental safety assessments remain pivotal approval hurdles.

10. Is the market consolidating or fragmenting?

Consolidation is intensifying—recent acquisitions by Zoetis and Ceva added regional pipelines; however, specialized biotechs entering with mRNA and VLP platforms keep the competitive arena dynamic, balancing scale versus innovation.

Contact for Full Report

Loading report content...

Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Size, Share & Forecast Analysis 2025–2033

Market Snapshot

Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Segmentation

Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines market size?

2. How fast is the market forecast to grow through 2030?

3. What are the key drivers fueling demand?

4. Which major challenges restrain growth?

5. Which regions lead consumption and innovation?

6. Who are the top companies competing today?

7. What future opportunities offer the highest upside?

8. How is technology reshaping vaccine development?

9. How does the regulatory landscape affect launches?

10. Is the market consolidating or fragmenting?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Segmentation

Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Porcine Reproductive Respiratory Syndrome (PRRS) Vaccines market size?

2. How fast is the market forecast to grow through 2030?

3. What are the key drivers fueling demand?

4. Which major challenges restrain growth?

5. Which regions lead consumption and innovation?

6. Who are the top companies competing today?

7. What future opportunities offer the highest upside?

8. How is technology reshaping vaccine development?

9. How does the regulatory landscape affect launches?

10. Is the market consolidating or fragmenting?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation